Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korea Seeks Two-Track Strategy For COVID-19 Drugs, Vaccines

Moves To Secure Foreign Supplies If Necessary

Executive Summary

As a recent increase in silent virus spreaders in metropolitan areas raises concerns, South Korea unveils policy measures to support the development of COVID-19 drugs and vaccines, as well as to secure imports of such products if necessary.

You may also be interested in...



Korea To Keep Tight Policy Focus On COVID-19 This Year

South Korea is ramping up policy and financial support in its continuing efforts to control COVID-19, with new drugs and vaccines set to benefit amid broader infectious disease control measures. 

Celltrion Progresses COVID-19 Antibody Therapeutic, Pricing Will Be Key

Celltrion presses ahead with Phase I study of COVID-19 antibody therapeutic, encouraged by the support of the South Korean government. The firm also urges global cooperation to lower prices of COVID-19 drugs and vaccines to end the global pandemic.

New Korean Accounting Guidelines Aim For More Flexible Biopharma Practices

South Korea moves to lay out clearer accounting guidelines related to R&D costs for pharma and biotech companies, making improvements to earlier official guidance in 2018 in order to ease uncertainties and help foster the sector.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS142319

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel